Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo; Ipilimumab (Yervoy) Every 3 Weeks for 12 Weeks Versus Observation

Trial Profile

Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo; Ipilimumab (Yervoy) Every 3 Weeks for 12 Weeks Versus Observation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ADMEC; ADMEC- O; DeCOG/ADO study
  • Most Recent Events

    • 04 Sep 2019 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
    • 04 Sep 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Mar 2022.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top